A modified version of the interlocking finger test as a bedside screening test for visuospatial deficits and dementia in Parkinson’s disease

Nele Schmidt¹ | Tim Strohmaier² | Karsten Witt¹,³

¹Department of Neurology, University Oldenburg, Oldenburg, Germany
²Förde Praxis, Schönberger Straße 166, Kiel, Germany
³Research Center of Neurosensory Sciences, University Oldenburg, Oldenburg, Germany

Correspondence
Nele Schmidt, Department of Neurology, University Oldenburg, Steinweg 13-17, 26122 Oldenburg, Germany.
Email: nele.schmidt@uni-oldenburg.de

Abstract

Introduction: Objective of this study was to examine if the Interlocking Finger Test (ILFT) is a suitable bedside screening test for visuospatial functions and/or dementia in Parkinson’s disease (PD) patients aiming to facilitate the diagnosis of a dementia syndrome associated with posterior cortical and temporal lobe dysfunction according to the dual syndrome hypothesis (frontostriatal vs. posterior cortical cognitive impairment).

Methods: Forty-seven PD patients were assessed with the ILFT and an extensive cognitive test battery. The ILFT was carried out in the original version as well as in three modified versions of the test including a fifth figure and/or a more complex rating system, leading to four different ILFT scores (named after the maximum achievable scoring result: ILFT 4, ILFT 5, ILFT 12, and ILFT 15). We conducted a correlation analysis to reveal associations between the ILFT scores and cognitive as well as motor impairments. Receiver operating curve (ROC) analyses were calculated to evaluate the ability of the ILFT scores to predict visuospatial impairments and dementia.

Results: ILFT scores correlated significantly with global cognition, visuospatial functions, memory, attention, and age (p < .0125) but not with executive functions, language, education, depression, and motor impairment. The ROC analyses revealed ILFT 15 as best predictor for visuospatial deficits and dementia with an area under the curve of .82 and .88, respectively.

Conclusion: The ILFT is suitable for detecting symptoms of the posterior cortical degeneration syndrome according to the dual syndrome hypothesis. We recommend the use of the modified test version ILFT 15.

KEYWORDS
dual syndrome hypothesis, Interlocking Finger Test, Parkinson’s disease, Parkinson’s disease dementia, screening test
INTRODUCTION

Cognitive impairment is a common nonmotor symptom in Parkinson’s disease (PD). The prevalence of mild cognitive impairment in PD is 40% (Baiano et al., 2020) and the prevalence of dementia in PD is 24–31% (Aarsland et al., 2005). Besides executive dysfunctions and impairments in memory and attention, PD patients often show visuospatial deficits (Aarsland et al., 2010; Curtis et al., 2019; Fernandez-Baizan et al., 2020; Muslimovic et al., 2005) including impairments in visuospatial perception, orientation, or construction. Deficits in visuospatial abilities increase in the course of the disease (Muslimovic et al., 2007) and initially more severe impairments are predictive for the progression of cognitive impairment in PD (Stepkina et al., 2010). Furthermore, visuospatial deficits not only discriminate patients with mild cognitive impairment from those with dementia (Biundo et al., 2014) but are also of prognostic importance regarding the later conversion to development of PD dementia. It was shown that early deficits in posterior cortically based cognitive (e.g., visuoconstructive) tasks that are associated with Lewy body deposition in these areas lead to subsequent dementia while cognitive deficits that are associated with a dopamine modulated frontal–striatal network dysfunction (e.g., executive functions) do not (Williams-Gray et al., 2007; Williams-Gray et al., 2009). Based on these and other study results on longitudinal cognitive impairment patterns, Kehagia et al. (2013) proposed the dual syndrome hypothesis which differentiates between two different, partly overlapping syndromes: (1) a dopamine modulated frontal-striatal network dysfunction in nondemented PD patients which is present at early disease stages and leads to executive and working memory impairments and (2) a dementia syndrome associated with more posterior cortical degeneration, temporal lobe dysfunction, and cholinergic loss characterized by prodomal visuospatial and semantic fluency deficits.

Distinguishing between these two cognitive syndromes in PD at an early disease stage is important to identify specific cognitive risk profiles, especially with regard to different treatment options. While frontostriatal dysfunctions can be improved by dopaminergic treatment (although they are susceptible to overdosing effects), patients with more posterior cortical deficits can benefit from cholinergic treatment (Kehagia et al., 2013). Various tests are available for diagnosing visuospatial deficits which are highly sensitive to the posterior cortical syndrome, however, upper limb motor impairments, tremor, impaired vision, or bedriddenness can be challenging for the neuropsychological diagnostic procedure in PD patients. To our knowledge, a validated bedside screening test for visuospatial deficits is not available so far. The Interlocking Finger Test (ILFT) by Moo et al. (2003) was developed as a screening for parietal lobe dysfunction and was used to detect bimanual apraxia in patients with Alzheimer’s disease (Sanin & Benke, 2017). The test consists of four nonsymbolic bimanual gestures which are demonstrated by the examiner and the subject must imitate these gestures. The authors found significant correlations between the ILFT and visuospatial tests (Clock Drawing, Rey-Osterrieth Complex Figure Test) and showed that the ILFT can predict parietal lobe dysfunction with a good sensitivity and a moderate specificity in a heterogeneous patient group (Moo et al., 2003). In PD patients, the ILFT correlated significantly with visuospatial functions (Clock Drawing Test) as well as with other cognitive domains (e.g., executive functions, memory), and was able to discriminate patients with dementia from those without it with a good specificity and a moderate sensitivity (Souza et al., 2016). In this study, we examined whether the ILFT is a suitable bedside screening test for visuospatial functions and/or dementia aiming to facilitate the diagnosis of the posterior cortical cognitive syndrome in PD. Furthermore, we examined if the predictive ability of the ILFT can be improved by modifying the rating system and adding an additional figure as the original test version has a small scoring range of only 0 to 4 points.

METHODS

2.1 Patients

Forty-seven patients with PD diagnosed according to the UK Parkinson’s Disease Society Brain Bank criteria (Hughes et al., 1992) were included in the analyses. Exclusion criteria were any neurological disorder other than PD and deep brain stimulation. The study was approved by the local ethics committee. All procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2013. All participants gave their informed consent to participate in the study in written form.

2.2 Interlocking Finger Test

All patients executed the ILFT. In this test, the investigator demonstrates consecutively nonsymbolic bimanual gestures, and the participants are asked to imitate these figures, one at a time, as accurate as possible. For subsequent evaluation, photos of the finished hand positions were taken. The original version of the ILFT includes four figures. They are scored with one point for each correctly imitated interlocking finger component of the figure regardless of the noninterlocking fingers or posture of the arms. In our study, we made two modifications of the ILFT: (1) a fifth figure was added (all figures are shown in the Figure S1) and (2) a more complex rating system was developed. In the modified rating system, three points were given for each figure. One point was given when the interlocking finger component including all fingers which are directly interlocked with the fingers of the other hand was imitated accurately. Therefore, the first point corresponds with the original test score by Moo et al. (2003). The second point was given when the noninterlocking fingers were placed correctly. The third point was given when both hands were orientated correctly to each other and to the participant’s body irrespective of the individual fingers. The score for each figure was therefore ranging from 0 to 3. According to these modifications, four different test scores were calculated, named after the maximum achievable scoring result: ILFT 4 (4 figures, original one-point scoring system), ILFT 5 (5 figures, original one-point scoring
system), ILFT 12 (4 figures, modified three-point scoring system), and ILFT 15 (5 figures, modified three-point scoring system).

2.3 | Cognitive functioning and clinical data

We used the Mini Mental State Examination (MMSE; Folstein et al., 1975) and the Parkinson Neuropsychometric Dementia Assessment (PANDA; Kalbe et al., 2008) as screening instruments for global cognitive functioning. Furthermore, we conducted an extensive neuropsychological test battery covering the following domains:

- Visuospatial functions (Consortium to Establish a Registry for Alzheimer’s Disease/CERAD, Morris et al., 1989: Constructional praxis copy; Leistungsprüfsystem 50+, Sturm et al., 1993: Mental rotation and Spatial sense).
- Executive functions (CERAD: lexical and phonemic fluency tests, Trail Making Test B/A; Wechsler Memory Scale—Revised, Härtling et al., 2000: Digit span reversed; Modified Card Sorting Test, Nelson, 1976: categories completed and perseverative errors).
- Attention (Brief Test of Attention, Schretlen, 1997; Stroop Test, Bäumler, 1985: reaction time).
- Memory (CERAD: Word list Learning and Recall, Constructional praxis recall), and
- Language (CERAD: Boston Naming Test).

Based on these tests, the patients were classified into PD with and without visuospatial impairments, and with and without dementia, respectively. Visuospatial impairment was diagnosed if a patient scored ≥ 1.5 standard deviations below normative data in at least one test assigned to the visuospatial domain. Dementia was diagnosed according to the Movement Disorder Society Task Force criteria (Emre et al., 2007) including (1) cognitive test scores ≥ 1.5 standard deviations below normative data in at least two different cognitive domains, (2) cognitive decline reported by the patient or a relative, and (3) significant impairment in activities of daily living.

Disease severity was rated with the Unified Parkinson’s disease rating scale motor score (UPDRS III; Fahn et al., 1987). The short form of the Geriatric Depression Scale (GDS; Sheikh & Yesavage, 1986) was used to assess depression. Levodopa equivalent daily dose (LEDD) was calculated according to Tomlinson et al. (2010).

2.4 | Statistical analyses

Statistical analyses were carried out using SPSS 25 (IBM SPSS Statistics for Windows, IBM Corp., Armonk, NY, USA) and SigmaPlot version 11.0 (Systat Software, Inc., San Jose, CA, USA). Given the fact that none of the ILFT scores were normal distributed according to the Shapiro-Wilk test, we used nonparametric statistical tests. To reveal associations between ILFT scores and sociodemographic, clinical, and neuropsychological data, Spearman’s rank correlation coefficients were calculated. As we computed correlations for all 4 ILFT scores, we used Bonferroni correction for multiple testing to decrease the risk of false positive errors. Therefore, effects were considered significant at p ≤ .0125 (.05/4). To evaluate the ability of the ILFT scores to predict visuospatial impairments and dementia, receiver operating characteristic (ROC) curve analyses were performed. To evaluate the diagnostic accuracy, sensitivity, specificity as well as positive and negative predictive value (PPV, NPV) were calculated. In addition, the Youden index (Youden, 1950) was computed, defined as the sum of sensitivity and specificity minus 1. To determine the interrater reliability of the ILFT scores, the ILFT rating was carried out by two independent raters (one psychologist and one physician) and Kendall’s tau-b coefficient was calculated.

3 | RESULTS

Twenty-eight of the PD patients were men and 19 women. Mean age was 66.67 (± 7.61). Disease duration was 7.04 years (± 3.72), UPDRS III score in the medical condition was 22.96 points (± 15.59), LEDD was 775.15 (± 363.21), and GDS score was 4.05 (± 3.40). Mean scores of the ILFT versions were 3.32 for ILFT 4 (± 0.86, range: 1–4), 4.21 for ILFT 5 (± 1.06, range: 1–5), 9.32 for ILFT 12 (± 2.00, range: 4–12), and 11.79 for ILFT 15 (± 2.58, range: 5–15). There were no group differences in ILFT scores between men and women (Mann-Whitney U tests, p = .612 to .956). All ILFT scores correlated significantly with age (r = −.509 to −.590, p < .001) but not with education, disease duration, severity of motor symptoms, LEDD, and depression (p ≥ .0125). All ILFT scores correlated significantly with at least one global cognition test (r = .316, p = .039 to r = .403, p = .007 for the MMSE and r = .524, p = .001 to r = .599, p < .001 for the PANDA). Regarding visuospatial test results, all ILFT scores correlated significantly with CERAD Constructional praxis (r = .415 to .500, p < .001 to p = .004) and LPS 50+ Spatial sense (r = .456 to .532, p < .001 to p = .004). Furthermore, there were significant correlations between ILFT results and CERAD memory scores (r = .370 to .593, p < .001 to .011) as well as Brief Test of Attention (r = .392 to .523, p < .001 to p = .008). Beyond that, the correlation analysis showed only sporadic significant results between isolated ILFT scores and phonematic word fluency and Stroop Test reaction time. All correlations can be seen in Table 1.

The ROC curve analyses using the ILFT scores to predict deficits in visuospatial functions showed that ILFT 15 was the ILFT version with the highest AUC (.82). The AUC significantly different from those of ILFT 4 (p = .02) and ILFT 5 (p = .02). No significant difference was found between the AUCs of ILFT 15 and ILFT 12 (p = .13). Best possible cutoff score was 12.5 with a Youden index of .51. PPV was .36 and NPV was 1. Regarding dementia, the analyses revealed ILFT 12 and ILFT 15 as best predictors with both an AUC of .88 and maximum Youden index of .58 and .59 at cutoff scores 9.5 and 10.5, respectively. PPV and NPV were .43 and .96, respectively, for the ILFT 12 and .64 and .92, respectively, for the ILFT 15. The AUC of the ILFT 12 differed significantly to those of ILFT 4 (p = .02) and ILFT 5 (p = .04) and the AUC of ILFT 15 was significantly different from the AUC of ILFT 4 (p = .04). There were no significant differences between the other AUC pairs. All results of
TABLE 1 Correlations between ILFT scores and sociodemographic, clinical, and cognitive data

|                          | ILFT 4          | ILFT 5          | ILFT 12         | ILFT15         |
|--------------------------|-----------------|-----------------|-----------------|----------------|
| **Sociodemographic variables** |                 |                 |                 |                |
| Age                      | -.509 (.001)    | -.527 (.001)    | -.572 (.001)    | -.590 (.001)   |
| Years of education       | .282 (.054)     | .291 (.047)     | .238 (.107)     | .237 (.109)    |
| **Clinical variables**   |                 |                 |                 |                |
| Disease duration         | -.025 (.870)    | -.035 (.816)    | -.067 (.654)    | -.054 (.719)   |
| UPDRS III                | -.158 (.290)    | -.170 (.254)    | -.258 (.080)    | -.206 (.165)   |
| LEDD (mg)                | -.003 (.985)    | -.008 (.959)    | .031 (837)      | .039 (.795)    |
| GDS                      | -.331 (.037)    | -.320 (.044)    | -.360 (.022)    | -.251 (.118)   |
| **Global cognitive abilities** |               |                 |                 |                |
| MMSE                     | .316 (.039)     | .341 (.025)     | .379 (.012)     | .403 (.007)    |
| PANDA                    | .524 (.001)     | .541 (.001)     | .584 (.001)     | .599 (.001)    |
| **Visuospatial functions** |               |                 |                 |                |
| CERAD: CP copy           | .415 (.004)     | .425 (.003)     | .419 (.003)     | .500 (.001)    |
| LPS S0+: mental rotation| .190 (.215)     | .214 (.164)     | .308 (.042)     | .340 (.024)    |
| LPS S0+: spatial sense   | .456 (.002)     | .469 (.001)     | .532 (.001)     | .513 (.001)    |
| **Executive functions**  |                 |                 |                 |                |
| TMT B/A                  | .127 (.399)     | .150 (.318)     | .053 (.727)     | .020 (.895)    |
| Digit span reversed      | .133 (.374)     | .132 (.378)     | .173 (.245)     | .190 (.202)    |
| CERAD: lexical fluency   | .207 (.163)     | .226 (.127)     | .305 (.037)     | .332 (.023)    |
| CERAD: phonemic fluency  | .186 (.216)     | .205 (.171)     | .379 (.009)     | .368 (.012)    |
| MCST: categories completed| .212 (.162)    | .238 (.115)     | .254 (.093)     | .292 (.051)    |
| MCST: perseverative errors| -.227 (.134)  | -.242 (.109)    | -.304 (.042)    | -.324 (.030)   |
| **Memory**               |                 |                 |                 |                |
| CERAD: word list learning| .375 (.009)     | .400 (.005)     | .425 (.003)     | .409 (.004)    |
| CERAD: word list recall  | .553 (.001)     | .569 (.001)     | .593 (.001)     | .552 (.001)    |
| CERAD: CP recall         | .370 (.011)     | .397 (.006)     | .422 (.003)     | .448 (.002)    |
| **Attention**            |                 |                 |                 |                |
| Brief Test of Attention  | .392 (.008)     | .401 (.006)     | .523 (.001)     | .501 (.001)    |
| Stroop Test: reaction time| -.325 (.032)  | -.344 (.022)    | -.455 (.002)    | -.458 (.002)   |
| **Language**             |                 |                 |                 |                |
| CERAD: Boston naming test| .227 (.060)     | .314 (.031)     | .283 (.054)     | .345 (.018)    |

Data are given as Spearman’s rank correlation (p value, two-tailed), significant results on p ≤ .0125 are in bold.

ILFT: Interlocking Finger Test; UPDRS: Unified Parkinson’s Disease Rating Scale; LEDD: L-dopa equivalent daily dose; GDS: Geriatric Depression Scale; MMSE: Mini Mental State Examination; PANDA: Parkinson Neuropsychometric Dementia Assessment; CERAD: Consortium to Establish a Registry for Alzheimer’s disease; LPS: Leistungsprüfsystem; TMT: Trail Making Test; MCST: Modified Card Sorting Test; CP: Constructional praxis.

the ROC curve analyses can be seen in Table 2 and Figure 1. Interrater reliability ranged from \( \tau = .755 \) to .891 for the four ILFT scores.

4 | DISCUSSION

We found significant correlations between ILFT scores and global cognition, visuospatial functions, memory, attention, and age but not between ILFT scores and executive functions, language, education, depression, and disease related variables such as disease duration and LEDD. Remarkably, the ILFT did not reflect motor impairment, given the lack of significant correlations between ILFT and motor scores. This specific property classified the ILFT as a cognitive rather than a motor task. The ROC analyses revealed ILFT 12 and ILFT 15 as best predictors for visuospatial deficits and dementia with good negative and moderate positive prediction values.

The correlation analysis showed that the ILFT highly correlated with global cognition, visuospatial functions, memory, and attention. These results are in line with a previous study in which significant correlations with tests of the same neuropsychological domains were found (Souza et al., 2016). We did not find relevant correlations with executive functions what is in line with Moo et al. (2003). As executive
functions are characteristic for the dopamine modulated fronto-
striatal network dysfunction syndrome (albeit except for semantic flu-
ency), the results support our hypothesis that the ILFT is sensitive for 
the posterior cortical degeneration syndrome according to the dual 
syndrome hypothesis. However, Souza et al. (2016) found correlations 
between the ILFT and several executive tests what might be due to 
the high rate of PD patients with a coexistence of a dementia syn-
drome in their study (40.5% vs. 21.3% in our study). Remarkably, the 
ILFT did not correlate significantly with any disease related variable, 
although it is a common problem in clinical praxis that motor impair-
ment affects visuospatial (especially visuoconstructive) test perfor-
ance in PD. We found negative correlations between ILFT and age, 
indicating that older people tended to achieve lower ILFT scores. An 
age-dependency was also shown by Souza et al. (2016) who supposed 
that the ILFT is able to detect subtle cognitive changes associated with 
aging. The result is in accord with the fact that older age is a significant 
predictor for dementia risk in PD (Williams-Gray et al., 2009). Moo et al. 
(2003) did not find significant correlations between ILFT and age; how-
ever, only 38 out of 69 patients were included in this calculation what 
may have biased the results.

The ROC curve analyses showed good negative prediction values 
for predicting visuospatial deficits and dementia in PD patients with 
no or only low risk of false negative results, indicating that the ILFT 
is suitable for the use as a bedside screening test. The positive prediction 
values of the ILFT were moderate, meaning that there is a higher 
chance of false positive results. Therefore, patients with a result below 
the cut-off score must undergo a formal neuropsychological examina-
tion to verify the ILFT result what is in line with the nature of a screen-
ing test. The predictive values of our study are comparable to those of 
previous studies with PD (Souza et al., 2016) and AD patients (Sanin & 
Benke, 2017). The fact that motor impairments did not affect the ILFT 
result and its easy implementation with a test duration of a few minutes 
maximum and no need for test material or equipment (e.g., table, pen-
cil, watch) argue for the ILFT as an appropriate screening instrument. 
Furthermore, the test showed good interrater reliability.

There were significant improvements in the prediction of visuo-
spatial deficits and dementia when using the modified versions of the ILFT. 
For predicting visuospatial deficits, ILFT 15 turned out to be the best 
predictor according to AUC and Youden index. Therefore, the ILFT 15 
is recommended as bedside screening test for the diagnosis of visuo-
spatial deficits. At a result of 12 points or lower, an extensive neu-
ropsychological testing should be carried out. Regarding the predic-
tion of PD dementia, ILFT 15 is the best predictor with a slightly higher 
Youden index as the ILFT 12 which is why we here also recommend the 
modified version ILFT 15 that contains an additional figure and a more 
complex rating system than the original. Cut-off for prediction of PD 
dementia is 10.5, meaning that a score of 10 or lower entails further 
diagnostic procedure.

A limitation of the study is that visuospatial functions are a mul-
tidimensional construct which could not be completely represented 
in the cognitive test battery. However, even in a formal neuropsycho-
logical testing are often isolated tests used that are not covering the 
entire spectrum of visuospatial deficits. Furthermore, long-term stud-
ies examining if patients with deficits in the ILFT will develop a demen-
tia syndrome in the course of the disease are necessary to verify our 
results.

In summary, the ILFT significantly correlated with visuospatial func-
tions, memory, attention, global cognitive abilities, and age indicating 
that it is suitable for detecting symptoms of the posterior cortical 
degeneration syndrome according to the dual syndrome hypothesis.
We recommend the use of ILFT 15 with cut-off scores of 12.5 for 
predicting visuospatial deficits or 10.5 for predicting PD dementia, 
respectively.

ACKNOWLEDGMENTS
For this study, part of the data was generated within the LAND-
SCAPE study. The LANDSCAPE study is part of the Competence Net-
work Degenerative Dementias (KNDD), which was funded by the Ger-
man Federal Ministry of Education and Research (project number 
01GI1008C).

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the 
corresponding author upon reasonable request.

### TABLE 2
Diagnostic values of the receiver operating characteristic curve analyses for the Interlocking Finger Test

| Test            | Sens. | Spec. | Y    | PPV | NPV  | Cut-off value | AUC  | SE  | 95% CI     | p  |
|-----------------|-------|-------|------|-----|------|---------------|------|-----|------------|----|
| Prediction of visuospatial deficits |       |       |      |     |      |               |      |     |            |    |
| ILFT 4          | .7    | .59   | .29  | .32 | .88  | 3.5           | .69  | 0.10 | 0.50 to 0.88 | .067 |
| ILFT 5          | .7    | .59   | .29  | .32 | .88  | 4.5           | .69  | 0.10 | 0.50 to 0.89 | .063 |
| ILFT 12         | .60   | .81   | .41  | .46 | .88  | 8.5           | .77  | 0.08 | 0.61 to 0.93 | .009 |
| ILFT 15         | 1.00  | .51   | .51  | .36 | 1.00 | 12.5          | .82  | 0.06 | 0.70 to 0.95 | .002 |
| Prediction of dementia |       |       |      |     |      |               |      |     |            |    |
| ILFT 4          | .80   | .62   | .42  | .36 | .92  | 3.5           | .77  | 0.09 | 0.60 to 0.94 | .009 |
| ILFT 5          | .80   | .62   | .42  | .36 | .92  | 4.5           | .78  | 0.09 | 0.60 to 0.95 | .007 |
| ILFT 12         | .90   | .68   | .58  | .43 | .96  | 9.5           | .88  | 0.06 | 0.77 to 0.99 | .000 |
| ILFT 15         | .7    | .89   | .59  | .64 | .92  | 10.5          | .88  | 0.06 | 0.77 to 0.99 | .000 |

Sens.: sensitivity; Spec.: specificity; Y: Youden’s index; PPV: positive predictive value; NPV: negative predictive value; AUC: area under curve; SE: standard error; CI: confidence interval.
FIGURE 1 Receiver operating characteristic (ROC) curves of the four Interlocking Finger Test (ILFT) versions. ROC curves demonstrate sensitivity (true positive rate) and 1 – specificity (false positive rate) of the ILFT according to the diagnosis of (a) visuospatial deficits and (b) Parkinson’s disease dementia. AUC: area under the curve

ORCID
Nele Schmidt https://orcid.org/0000-0001-9777-4085

REFERENCES
Aarsland, D., Bronnick, K., Williams-Gray, C., Weintraub, D., Marder, K., Kulisevsky, J., Burn, D., Barone, P., Pagonabarraga, J., Allcock, L., Santangelo, G., Foltynie, T., Janvin, C., Larsen, J. P., Barker, R. A., & Emre, M. (2010). Mild cognitive impairment in Parkinson disease: A multicenter pooled analysis. Neurology, 75, 1062–1069. https://doi.org/10.1212/WNL.0b013e3181f39d0e

Aarsland, D., Zaccai, J., & Brayne, C. (2005). A systematic review of prevalence studies of dementia in Parkinson’s disease. Movement Disorders, 20, 1255–1263. https://doi.org/10.1002/mds.20527

Baiano, C., Barone, P., Trojano, L., & Santangelo, G. (2020). Prevalence and clinical aspects of mild cognitive impairment in Parkinson’s disease: A meta-analysis. Movement Disorders, 35, 45–54. https://doi.org/10.1002/mds.27902

Bäumler, G. (1985). Farbe-Wort-Interferenztest (FWIT) nach J. R. Stroop. Göttingen: Hogrefe.

Biundo, R., Weis, L., Facchinì, S., Formento-Dojot, P., Vallezlunga, A., Pilleri, M., & Antonini, A. (2014). Cognitive profiling of Parkinson disease patients with mild cognitive impairment and dementia. Parkinsonism & Related Disorders, 20, 394–399. https://doi.org/10.1016/j.parkreldis.2014.01.009

Curtis, A. F., Masellis, M., Ciamillo, R., Davidson, H., & Tierney, M. C. (2019). Cognitive profile of non-demented Parkinson’s disease: Meta-analysis of domain and sex-specific deficits. Parkinsonism & Related Disorders, 60, 32–42. https://doi.org/10.1016/j.parkreldis.2018.10.014

Emre, M., Aarsland, D., Brown, R., Burn, D. J., Duyckaerts, C., Mizuno, Y., Broe, G. A., Cummings, J., Dickson, D. W., Gauthier, S., Goldman, J., Goetz, C., Korczyn, A., Lees, A., Levy, R., Litvan, I., McKeith, I., Olanow, W., Poewe, W., Bubois, B. (2007). Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Movement Disorders, 22, 1689–1707. https://doi.org/10.1002/mds.21507

Fahn, S., & Elton, R. L., & Members of the UPDRS Development Committee (1987). Unified Parkinson’s disease rating scale. In S. Fahn, C. D. Marsden, D. B. Calne, & M. Goldstein (Eds.), Recent developments in Parkinson’s Disease (pp. 153–164). Florham Park: Macmillan Health Care Information.

Fernandez-Baizan, C., Paula Fernandez Garcia, M., Diaz-Caceres, E., Baiano, C., Barone, P., Trojano, L., & Santangelo, G. (2020). Prevalence and specific dementia assessment (PANDA) instrument.

Fillenbaum, G., Mellits, E. D., & Clark, C. (1989). The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer’s disease. Neurology, Neurosurgery, and Psychiatry, 52, 394–399. https://doi.org/10.1136/jnnp.52.3.394

Hätting, C., Markowitsch, H. J., Neufeld, H., Calabrese, P., Deisinger, K., & Kessler, J. (2000). WMS-R, Wechsler Gedächtnistest - Revidierte Fassung. Bern: Hans Huber.

Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992). Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: A clinico-pathological study of 100 cases. Journal of Neurology, Neurosurgery, and Psychiatry, 55, 181–184.

Kalbe, E., Calabrese, P., Kohn, N., Hilker, R., Riedel, O., & Wittchen, H. U., Dodel, R., Otto, J., Ebersbach, G., & Kessler, J. (2008). Screening for cognitive deficits in Parkinson’s disease with the Parkinson neuropsychometric dementia assessment (PANDA) instrument. Parkinsonism & Related Disorders, 14, 93–101. https://doi.org/10.1016/j.parkreldis.2007.06.008

Kehagia, A. A., Barker, R. A., & Robbins, T. W. (2013). Cognitive impairment in Parkinson’s disease: The dual syndrome hypothesis. Neurodegenerative Diseases, 11, 79–92. https://doi.org/10.1159/000341998

Moo, L. R., Slotnick, S. D., Tesoro, M. A., Zee, D. S., & Hart, J. (2003). Interlocking finger test: A bedside screen for parietal lobe dysfunction. Journal of Neurology, Neurosurgery, and Psychiatry, 74, 530–532.

Morris, J. C., Heyman, A., Mohs, R. C., Hughes, J. P., van Belle, G., & Fillenbaum, G., Mellits, E. D., & Clark, C. (1989). The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD), Part I. Clinical and neuropsychological assessment of Alzheimer’s disease. Neurology, 39, 394–399.

Muslimovic, D., Post, B., Speelman, J. D., & Schmand, B. (2005). Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology, 65, 1239–1245. https://doi.org/10.1212/01.wnl.0000180516.69442.95

Muslimovic, D., Schmand, B., Speelman, J. D., & de Haan, R. J. (2007). Course of cognitive decline in Parkinson’s disease: A meta-analysis. Journal of the
Nelson, H. E. (1976). A modified card sorting test sensitive to frontal lobe defects. Cortex: A Journal Devoted to the Study of the Nervous System and Behavior, 12, 313–324.

Sanin, G. N., & Benke, T. (2017). Bimanual gesture imitation in Alzheimer’s disease. Journal of Alzheimer’s Disease, 57, 53–59. https://doi.org/10.3233/JAD-160680

Schretlen, D. (1997). Brief Test of Attention. Lutz, Florida: Psychological Assessment Resources.

Sheikh, J. I., & Yesavage, J. A. (1986). Geriatric Depression Scale (GDS): Recent evidence and development of a shorter version. In T. L. Brink (Ed.), Clinical gerontology: A guide to assessment and intervention (pp. 165–173). New York: The Haworth Press.

Souza, C. P., Oliveira, G. N., Foss, M. P., & Tumas, V. (2016). The interlocking finger test in patients with Parkinson’s disease and healthy subjects. Journal of Clinical Neuroscience, 29, 145–148. https://doi.org/10.1016/j.jocn.2015.09.026

Stepkina, D. A., Zakharov, V. V., & Yakhno, N. N. (2010). Cognitive impairments in progression of Parkinson’s disease. Neuroscience and Behavioral Physiology, 40, 61–67. https://doi.org/10.1007/s11055-009-9223-6

Sturm, W., Willmes, K., & Horn, W. (1993). Leistungsprüfsystem für 50- bis 90-Jährige. Göttingen: Hogrefe.

Tomlinson, C. L., Stowe, R., Patel, S., Rick, C., Gray, R., & Clarke, C. E. (2010). Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Movement Disorders, 25, 2649–2653. https://doi.org/10.1002/mds.23429

Williams-Gray, C. H., Foltynie, T., Brayne, C. E. G., Robbins, T. W., & Barker, R. A. (2007). Evolution of cognitive dysfunction in an incident Parkinson’s disease cohort. Brain, 130, 1787–1798. https://doi.org/10.1093/brain/awm111

Williams-Gray, C. H., Evans, J. R., Goris, A., Foltynie, T., Ban, M., & Robbins, T. W., Brayne, C., Kolachana, B. S., Weinberger, D. R., Sawcer, S. J., & Barker, R. A. (2009). The distinct cognitive syndromes of Parkinson’s disease: 5 year follow-up of the CamPaIGN cohort. Brain, 132, 2958–2969. https://doi.org/10.1093/brain/awp245

Youden, W. J. (1950). Index for rating diagnostic tests. Cancer, 3, 32–35.

SUPPORTING INFORMATION

Additional supporting information may be found in the online version of the article at the publisher’s website.

How to cite this article: Schmidt, N., Strohmaier, T., & Witt, K. (2022). A modified version of the interlocking finger test as a bedside screening test for visuospatial deficits and dementia in Parkinson’s disease. Brain and Behavior, 12, e2516. https://doi.org/10.1002/brb3.2516